Efficacy and pharmacokinetics of a new controlled-release morphine sulfate 200-mg tablet.
Nineteen of 25 patients (14 female) with advanced malignant disease completed a randomized controlled trial of a new high-dose (200 mg) tablet formulation of controlled-release morphine. Compared with the currently available 100-mg tablets there were no differences in pain severity or adverse effects with the new formulation. In four patients, full 12-hr plasma morphine concentration profiles at steady state were obtained and showed no significant differences between the same dose provided as 100-mg and 200-mg tablets in Cmax, tmax, or other pharmacokinetic indices.
Hanks
G W
GW
Royal Marsden Hospital, London, United Kingdom.
Hanna
M
M
Finlay
I
I
Radstone
D J
DJ
Keeble
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010147:Pain Measurement
D003692:Delayed-Action Preparations; D009020:Morphine